Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans (Q37799412)

23 August 2017

title

Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans (English)

1 reference

23 August 2017

0 references

Andrew J Bett

1

1 reference

23 August 2017

Sheri A Dubey

2

1 reference

23 August 2017

Devan V Mehrotra

3

1 reference

23 August 2017

Liming Guan

4

1 reference

23 August 2017

Romnie Long

5

1 reference

23 August 2017

Kiersten Anderson

6

1 reference

23 August 2017

Kelly Collins

7

1 reference

23 August 2017

Christine Gaunt

8

1 reference

23 August 2017

Rose Fernandez

9

1 reference

23 August 2017

Suzanne Cole

10

1 reference

23 August 2017

Steve Meschino

11

1 reference

23 August 2017

Aimin Tang

12

1 reference

23 August 2017

Xiao Sun

13

1 reference

23 August 2017

Sanjay Gurunathan

14

1 reference

23 August 2017

Jim Tartaglia

15

1 reference

23 August 2017

Michael N Robertson

16

1 reference

23 August 2017

John W Shiver

17

1 reference

23 August 2017

Danilo R Casimiro

18

1 reference

23 August 2017

language of work or name

English

0 references

publication date

23 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

28

1 reference

23 August 2017

issue

50

1 reference

23 August 2017

page(s)

7881-7889

1 reference

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Site-specific mutagenesis of AIDS virus reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Site-directed mutagenesis of the conserved Asp-443 and Asp-498 carboxy-terminal residues of HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Point mutations in conserved amino acid residues within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNase H function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Use of nonionic block copolymers in vaccines and therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Evaluation of cellular immune responses in subjects chronically infected with HIV type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

inferred from DOI database lookup

7 January 2021

based on heuristic

Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.079

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.09.079

1 reference

23 August 2017

1 reference